These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34955693)

  • 1. A Systematic Review of the Stability of Extemporaneous Pediatric Oral Formulations.
    Belayneh A; Tessema Z
    ScientificWorldJournal; 2021; 2021():8523091. PubMed ID: 34955693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
    Pabari RM; McDermott C; Barlow J; Ramtoola Z
    Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids.
    Ghulam A; Keen K; Tuleu C; Wong IC; Long PF
    Ann Pharmacother; 2007 May; 41(5):857-60. PubMed ID: 17440007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extemporaneous drug formulations.
    Nahata MC; Allen LV
    Clin Ther; 2008 Nov; 30(11):2112-9. PubMed ID: 19108799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical stability of captopril and enalapril extemporaneous formulations for pediatric patients.
    Casas M; Álvarez J; Lucero MJ
    Pharm Dev Technol; 2015 May; 20(3):271-8. PubMed ID: 24279906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the Physical, Chemical and Microbiological Stability of Losartan Potassium 5 mg/mL Extemporaneous Oral Liquid Suspension.
    Foley L; Toney J; Barlow JW; O'Connor M; Fitzgerald-Hughes D; Ramtoola Z
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33435555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
    Brion F; Nunn AJ; Rieutord A
    Acta Paediatr; 2003 Apr; 92(4):486-90. PubMed ID: 12801118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical appraisal of commercially available suspending vehicles for extemporaneous compounding of cardiovascular medicines: physical and chemical stability mini review.
    Thrimawithana TR; D'Amore S; Dib Y; Fadavi Firooz N; Fakhouri W; Saeed A; Allahham A
    Pharm Dev Technol; 2019 Jun; 24(5):529-538. PubMed ID: 30238838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.
    Lam MS
    Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension.
    Sae Yoon A; Sawatdee S; Woradechakul C; Sae Chee K; Atipairin A
    Sci Pharm; 2015; 83(4):659-70. PubMed ID: 26839846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of miniaturized near-infrared spectroscopy for quality control of extemporaneous orodispersible films.
    Foo WC; Widjaja E; Khong YM; Gokhale R; Chan SY
    J Pharm Biomed Anal; 2018 Feb; 150():191-198. PubMed ID: 29247960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt.
    Pramar YV; Mandal TK; Bostanian LA; Le G; Morris TC; Graves RA
    Int J Pharm Compd; 2021; 25(2):169-175. PubMed ID: 33798117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt.
    Pramar YV; Mandal TK; Bostanian LA; Kader C; Morris TC; Graves RA
    Int J Pharm Compd; 2021; 25(5):431-439. PubMed ID: 34623970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric drug formulations: challenges and potential solutions.
    Nahata MC
    Ann Pharmacother; 1999 Feb; 33(2):247-9. PubMed ID: 10084423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extemporaneous benznidazole oral suspension prepared from commercially available tablets for treatment of Chagas disease in paediatric patients.
    García MC; Manzo RH; Jimenez-Kairuz AF
    Trop Med Int Health; 2015 Jul; 20(7):864-70. PubMed ID: 25784402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-friendly extemporaneous formulation of bisoprolol: application to stability and bioavailability studies.
    El-Masry SM; Helmy SA; Helmy SAM; Mazyed EA
    Drug Deliv Transl Res; 2023 Mar; 13(3):795-810. PubMed ID: 36192532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules.
    Winiarski AP; Infeld MH; Tscherne R; Bachynsky M; Rucki R; Nagano-Mate K
    J Am Pharm Assoc (2003); 2007; 47(6):747-55. PubMed ID: 18032138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical and microbiological stability of two news oral liquid formulations of clonidine hydrochloride for pediatric patients.
    Merino-Bohórquez V; Delgado-Valverde M; García-Palomo M; Dávila-Pousa MC; Cañete C; Villaronga M; Rodriguez-Marrodán B; López-Rojas R; Cameán-Fernández M;
    Pharm Dev Technol; 2019 Apr; 24(4):465-478. PubMed ID: 30124097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A proposed pediatric biopharmaceutical classification system for medications for chronic diseases in children.
    Bhatt-Mehta V; Hammoud H; Amidon GL
    Eur J Pharm Sci; 2020 Sep; 152():105437. PubMed ID: 32598914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding.
    Zhao F; Dave VS; Mar MZ; Perri JR
    Int J Pharm Compd; 2018; 22(5):433-439. PubMed ID: 30384342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.